Project Grant K24HL167910
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $197,640 to Dr. Lee Goeddel at Johns Hopkins University to conduct research on the relationship between cardiac output, renal perfusion, and the development of acute kidney injury in cardiac surgery patients. The project aims to leverage Dr. Goeddel's expertise in data science, biomarkers, and ultrasound imaging to better understand the mechanisms behind this...
- This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), will provide $267,000.00 to The Children's Hospital Corporation (doing business as Boston Children's Hospital) for a project titled "Multimodal Characterization of Cardiac-Neurodevelopmental Genes." The project aims to (1) identify mechanisms by which certain genetic syndromes lead to alterations in both heart and brain development,...
- This federal Project Grant award from the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training program (CFDA 93.859), provides $179,475 to The Children's Hospital of Philadelphia (CHOP) to conduct research on pediatric sepsis. The key objectives of the project are to define and validate a molecular subphenotyping model that can predict the severity of sepsis in children, and to test the reversibility of immune dysregulation through targeting...
- This federal Project Grant, awarded by the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research), supports research to assess the timing and risk of developing Persistent Inflammation, Immunosuppression, and Catabolism Syndrome (PICS) and sepsis in children following congenital heart defect (CHD) surgery. The $271,938 award to Vanderbilt University Medical Center (VUMC) will fund a deeper analysis of institutional databases to understand how this syndrome...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) will provide $156,340.00 over 5 years, starting on June 15, 2025, to Connecticut Children's Medical Center to develop and test a provider-focused intervention to improve health outcomes in pediatric sickle cell disease. The key products and services to be delivered under this award include: Literature reviews on provider communication and health outcomes in pediatric...
- This federal Project Grant award from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), under the Child Health and Human Development Extramural Research program (CFDA 93.865), provides $181,438 to The Children's Hospital of Philadelphia (CHOP) to conduct a prospective longitudinal study on neurocognitive outcomes and recovery trajectory for 180 school-aged pediatric sepsis survivors over 12 months. The key objectives are to evaluate the prevalence of...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $190,080 to the Ann & Robert H. Lurie Children's Hospital of Chicago to develop and pilot a cardiovascular health (CVH) screening and primary care referral program called "Champion Fathers" for expectant fathers. The key objectives are to: 1) determine how the transition to fatherhood impacts CVH metrics using data from the Coronary Artery Risk...
- This Project Grant award of $198,720.00 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research led by Dr. Anthony Sochet at The Johns Hopkins University to investigate the impact of invasive mechanical ventilation on functional fibrinolysis and thromboinflammation, and to develop an enhanced risk prediction model for hospital-acquired venous thromboembolism in critically ill children. The research aims to inform the design of...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $180,174 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Children's Hospital of Philadelphia Research Institute. The grant will fund a study to develop a framework for designing the next generation of pediatric acute respiratory distress syndrome (ARDS) clinical trials. Key objectives include: 1) Comparing heterogeneity of treatment effect (HTE) analysis methodologies in a trial of pediatric...
- This federal Project Grant award of $169,344 from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) aims to advance the management of critically ill adults with non-ARDS acute hypoxemic respiratory failure (NAHRF). The key objectives are to: 1) Develop clinical prediction models for mortality in NAHRF patients; 2) Apply machine learning to detect NAHRF subphenotypes associated with differential clinical outcomes; and 3) Use sequencing-based whole...
SYSTEMS BIOLOGY OF ACUTE AND CHRONIC MULTI-ORGAN FAILURE IN CHILDREN WITH CONGENITAL HEART DISEASE - PROJECT SUMMARY APPROXIMATELY 25% OF CHILDREN WITH CONGENITAL HEART DISEASE (CHD) REQUIRE INTERVENTION IN THE FIRST YEAR OF LIFE. ALTHOUGH SURGICAL MORTALITY HAS DECREASED, THE INCIDENCE OF ACUTE AND CHRONIC POSTOPERATIVE MORBIDITIES REMAINS HIGH. MORBIDITIES ARE PRIMARY DRIVERS OF HOSPITALIZATION, LONG-TERM OUTCOMES, AND COST, AND ARE MOST COMMON IN CHILDREN REQUIRING NEONATAL SURGERY AND THOSE UNDERGOING STAGED PALLIATION FOR SINGLE VENTRICLE HEART DISEASE (SVHD). WHILE OUR PATIENTS STRUGGLE WITH THESE MORBIDITIES DAILY, OUR UNDERSTANDING OF THE MECHANISMS AND MOLECULAR PHENOTYPES OF ORGAN INJURY/RECOVERY REMAIN LIMITED. OUR PRELIMINARY DATA SUGGEST THAT TARGETING A LIMITED NUMBER OF BIOMARKERS/PATHWAYS IS INSUFFICIENT TO ADDRESS THE COMPLICATED REALITY OF CHD. INSTEAD, DIAGNOSTIC APPROACHES ALLOWING SIMULTANEOUS MEASUREMENT OF HUNDREDS OF MOLECULES ("OMICS") PAIRED WITH HIGH DIMENSION DATA ANALYSIS TECHNIQUES COULD REPRESENT A BETTER STRATEGY. OUR TEAM HAS BEEN HIGHLY PRODUCTIVE IN DETAILING THE ACUTE METABOLOMIC AND PROTEOMIC RESPONSE TO CHD SURGERY. WE ALSO FOUND THAT THE ROBUST DATASETS GENERATED THROUGH THIS WORK PROVIDE AN EXCELLENT ENVIRONMENT FOR TRAINING JUNIOR RESEARCHERS IN DATA SCIENCE METHODS. UNDER THIS K24 PROPOSAL, WE WILL USE OUR TWO ESTABLISHED COHORTS (NEONATAL SURGERY AND LONGITUDINAL SVHD PALLIATION) TO EXPAND BEYOND THE ACUTE POSTOPERATIVE PERIOD, EXPLORING THE SYSTEMS BIOLOGY OF SUBACUTE AND CHRONIC MORBIDITY IN OUR CHD PATIENTS. WE WILL ALSO LEVERAGE THESE HIGH DIMENSION DATASETS TO TRAIN THE NEXT GENERATION OF RESEARCHERS INTERESTED IN USING DATA SCIENCE TECHNIQUES TO IMPROVE THE LIVES OF CHILDREN WITH CHD. OVERALL HYPOTHESIS: POSTOPERATIVE INJURY AND ABNORMAL DEVELOPMENT FOLLOWING CHD SURGERY RESULT IN DISRUPTION OF THE CIRCULATING PROTEOME AND METABOLOME DURING INITIAL INJURY, REPAIR, AND LONGITUDINAL GROWTH. SERIAL MEASUREMENTS OF THE PROTEOMIC AND METABOLOMIC SIGNATURE WILL VALIDATE NOVEL CANDIDATE BIOMARKERS OF KEY CHRONIC MORBIDITIES AND IDENTIFY PREVIOUSLY UNEXPLORED INTERACTIONS AMONG DIVERSE MOLECULAR PATHWAYS IN A SYSTEMS BIOLOGY APPROACH TO UNDERSTANDING THIS COMPLEX PATHOPHYSIOLOGY. SPECIFIC AIM 1 (NEW SCIENCE UNDER THE K24): UTILIZE PROXIMITY EXTENSION ASSAY TECHNOLOGY TO PERFORM LONGITUDINAL MEASUREMENT OF THE CIRCULATING PROTEOME IN THE CONVALESCENT PERIOD AFTER NEONATAL CHD SURGERY AND DETERMINE THE PROTEOMIC PHENOTYPE/CHANGES IN TARGETED PROTEIN BIOMARKERS PRECEDING TWO CRITICAL POSTOPERATIVE MORBIDITIES: SUBACUTE INTESTINAL INJURY AND CHRONIC NEURODEVELOPMENTAL DELAY. SPECIFIC AIM 2 (CAREER DEVELOPMENT): EXPAND MY SKILLS IN THE ANALYSIS OF OMICS AND DEEP CLINICAL DATA THROUGH A COMBINATION OF EXPERIENTIAL AND DIDACTIC TRAINING, WITH AN EMPHASIS ON LEARNING NOVEL STRATEGIES TO INTEGRATE AND ANALYZE MULTIPLE STREAMS OF HIGH DIMENSIONAL DATA. SPECIFIC AIM 3 (MENTORING): USING OUR ESTABLISHED COHORTS AS A TRAINING PLATFORM, DEVELOP A PIPELINE OF NEW PATIENT-ORIENTED PHYSICIAN-SCIENTISTS INTERESTED IN LEARNING AND APPLYING DATA SCIENCE METHODS TOWARDS MECHANISTIC, DIAGNOSTIC, AND THERAPEUTIC DISCOVERY IN CHILDREN WITH CHD.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $126.1k | 8/2/25 | ||
| Not listed | $126.1k | 8/2/24 |